Search

everythinglearnresearchcommunity

for

Search:↓

AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

A new diagnostic model can help better diagnose and understand Alopecia Areata.

Monoclonal antibodies are often linked to alopecia areata cases.

TH antibodies in vitiligo and AA patients recognize the same protein parts.

Machine learning can help identify biomarkers for personalized Pemphigus vulgaris treatment.

Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Adalimumab may cause severe hair loss in some patients.

ABCD1 gene mutations cause adrenomyeloneuropathy, leading to symptoms like limb weakness and spasticity, with management focusing on rehabilitation and spasticity treatment.

Adalimumab improved folliculitis decalvans in most patients.

Abatacept may help some people with alopecia areata regrow hair.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

Six months after COVID-19, most patients still had autoantibodies.

Anti-Desmocollin 3 antibodies can cause pemphigus-like symptoms in mice.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.

Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.

CD2 might be a new treatment target for patchy alopecia areata.

The patient with both scarring and non-scarring hair loss showed complex immune reactions and improved with steroid treatment.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Certain gene variations may increase the risk and severity of alopecia areata.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Biopsy can differentiate between alopecia areata and androgenic alopecia, and if more information is needed, testing for CD3 and CD8 can help.

New mutations in the SLC39A4 gene found in twins help understand the genetic cause of acrodermatitis enteropathica.

Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.

Anti-Desmocollin 3 antibodies can cause atypical pemphigus symptoms.

Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.